Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

New drug target found for cystic fibrosis lung disease

08.11.2012
Discovery could lead to new treatment for lung inflammation

Vancouver researchers have discovered the cellular pathway that causes lung-damaging inflammation in cystic fibrosis (CF), and that reducing the pathway’s activity also decreases inflammation. The finding offers a potential new drug target for treating CF lung disease, which is a major cause of illness and death for people with CF.

“Developing new drugs that target lung inflammation would be a big step forward,” says Dr. Stuart Turvey, who led the research. Dr. Turvey is the director of clinical research and senior clinician scientist at the Child & Family Research Institute and a pediatric immunologist at BC Children’s Hospital. He is an associate professor in the Department of Pediatrics at the University of British Columbia.

The research was published online last week in the Journal of Immunology.

For the study, researchers compared the immune response of normal lung cells with that of CF lung cells after exposing both types of cells to bacteria in the lab. In healthy cells, exposure to bacteria triggers the cell to secrete special molecules that attract immune cells to fight the infection.

In CF lung cells, the researchers discovered that a series of molecular events called the unfolded protein response is more highly activated. It causes the CF lung cells to secrete more molecules that attract an excessive amount of immune cells, which leads to increased inflammation.

They also found that treating the CF cells with a special chemical normalized the unfolded protein response and stabilized the cells’ immune response.

CF is the most common genetic disease affecting young Canadians. One in every 3600 children born in Canada has CF. There is no cure. A build-up of mucus in the lungs causes people with CF to be susceptible to bacterial lung infections, which trigger inflammation and swelling. Over time, the recurring cycle of infections and inflammation damages the lungs and can lead to the need for lung transplantation. The only treatments for lung inflammation are steroids and anti-inflammatory medications, which can have significant side effects.

The researchers are planning further study to validate these findings in a larger number of lung cell samples from people with CF.

This discovery resulted from a collaboration among Vancouver investigators and trainees based at the Child & Family Research Institute at BC Children’s Hospital, the University of British Columbia, and the Providence Heart + Lung Institute at St. Paul’s Hospital.

This research was funded by Cystic Fibrosis Canada and the Michael Smith Foundation for Health Research.

Jennifer Kohm | EurekAlert!
Further information:
http://www.cfri.ca

More articles from Health and Medicine:

nachricht UV light robot to clean hospital rooms could help stop spread of 'superbugs'
15.04.2015 | Texas A&M University

nachricht Heart cells regenerated in mice
14.04.2015 | Weizmann Institute of Science

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Forscher verschieben Moleküle auf Oberflächen: Nur halb so viel Kraft nötig wie theoretisch gedacht

Forscher der Universität Regensburg haben ein interessantes Phänomen aus der Welt der Quantenphysik entdeckt: Um ein Kohlenmonoxidmolekül auf einer Oberfläche seitlich zu verschieben, ist nur halb so viel Kraft erforderlich, wie theoretisch zu erwarten wäre.

Ein Team um Prof. Dr. Franz J. Gießibl vom Institut für Experimentelle und Angewandte Physik machte diese Beobachtung bei Versuchen mit einem...

Im Focus: Autoklavierbare LEDs für die Medizintechnik

Das neue Keramik-SMD-Design der Solidur™ TO LED ermöglicht komplexe Chipkonfigurationen in einem einzigen LED-Modul.

SCHOTT stellte vor kurzem seine neue autoklavierbare und hochbeständige Solidur™ LED-Produktlinie für Geräte und Instrumente der Medizin- und Dentaltechnik...

Im Focus: Astronomers reveal supermassive black hole's intense magnetic field

Astronomers from Chalmers University of Technology have used the giant telescope Alma to reveal an extremely powerful magnetic field very close to a supermassive black hole in a distant galaxy

Astronomers from Chalmers University of Technology have used the giant telescope Alma to reveal an extremely powerful magnetic field very close to a...

Im Focus: Eine „Flipper-Maschine“ für Atome und Photonen

Physiker vom MPQ, Caltech und ICFO haben ein neues Konzept entwickelt, durch Kombination von Nano-Photonik mit ultrakalten Atomen Quanten-Vielteilchensysteme zu simulieren und neue Materiezustände zu erzeugen.

Ultrakalte Atome in optischen Gittern, die durch die kreuzweise Überlagerung von Laserstrahlen entstehen, haben sich bereits als die meist versprechenden...

Im Focus: A “pin ball machine” for atoms and photons

A team of physicists from MPQ, Caltech, and ICFO proposes the combination of nano-photonics with ultracold atoms for simulating quantum many-body systems and creating new states of matter.

Ultracold atoms in the so-called optical lattices, that are generated by crosswise superposition of laser beams, have been proven to be one of the most...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Das Kaba Ideen Netzwerk geht in die nächste Runde

17.04.2015 | Veranstaltungen

VDI-Expertenforum: Effiziente Softwareentwicklung in der Medizintechnik

17.04.2015 | Veranstaltungen

Impflücken schließen. Die Europäische Impfwoche beginnt

17.04.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Das Kaba Ideen Netzwerk geht in die nächste Runde

17.04.2015 | Veranstaltungsnachrichten

ERP-Softwarehersteller HS zeigt mit neuer Webpräsenz Gesicht

17.04.2015 | Unternehmensmeldung

Schnelle und unkomplizierte Hilfe von HEIDENHAIN im Servicefall

17.04.2015 | Unternehmensmeldung